CoChat
Sign Up
Cited by 37Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

Open access
Sweis, Randy F., Luke, Jason J.·2017·Pharmacological Research
DOI 10.1016/j.phrs.2017.03.012PMC PMC5419683
Open this paper in CoChat — free account

Abstract

The concept of augmenting the immune system to eradicate cancer dates back at least a century. A major resurgence in cancer immunotherapy has occurred over the past decade since the identification and targeting of negative regulators with antibody therapies to augment the anti-tumor immune response. Unprecedented responses across a broad array of cancer types elevated this class of therapies to the forefront of cancer treatment. The most successful drugs to date target the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) pathways. The immune biology of these pathways was illuminated through thoughtful pre-clinical experiments over the past 20 years. The characterization of these negative immune regulators, also known as immune checkpoints, subsequently led to the successful clinical development four drugs in six different cancer types to date, and progress continues. Despite these successes, significant challenges remain including the development of predictive biomarkers, recognition and management of immune related toxicities, and elucidating and reversing mechanisms of primary and secondary resistance. Ongoing work is expected to build upon recent accomplishments and allow more patients to benefit from this class of therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2017.03.012

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 56

  1. McCarthy, 2006, The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, IOWA Orthop. J., 26, 154
  2. Schumacher, 2015, Neoantigens in cancer immunotherapy, Science, 348, 69, 10.1126/science.aaa4971 · DOI · Paper page
  3. Fuertes, 2013, Type I interferon response and innate immune sensing of cancer, Trends Immunol., 34, 67, 10.1016/j.it.2012.10.004 · DOI · Paper page
  4. Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J. Exp. Med., 208, 1989, 10.1084/jem.20101158 · DOI · Paper page
  5. Sharpe, 2002, The B7-CD28 superfamily, Nat. Rev. Immunol., 2, 116, 10.1038/nri727 · DOI
  6. June, 1994, The B7 and CD28 receptor families, Immunol. Today, 15, 321, 10.1016/0167-5699(94)90080-9 · DOI
  7. Brunet, 1987, A new member of the immunoglobulin superfamily–CTLA-4, Nature, 328, 267, 10.1038/328267a0 · DOI
  8. Harper, 1991, CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location, J. Immunol., 147, 1037, 10.4049/jimmunol.147.3.1037 · DOI
  9. Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X · DOI · Paper page
  10. Walunas, 1996, CTLA-4 ligation blocks CD28-dependent T cell activation, J. Exp. Med., 183, 2541, 10.1084/jem.183.6.2541 · DOI
  11. Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6 · DOI · Paper page
  12. Fallarino, 1998, B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28, J. Exp. Med., 188, 205, 10.1084/jem.188.1.205 · DOI
  13. Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 · DOI · Paper page
  14. Gavin, 2007, Foxp3-dependent programme of regulatory T-cell differentiation, Nature, 445, 771, 10.1038/nature05543 · DOI
  15. Fallarino, 2003, Modulation of tryptophan catabolism by regulatory T cells, Nat. Immunol., 4, 1206, 10.1038/ni1003 · DOI
  16. Ishida, 1992, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J., 11, 3887, 10.1002/j.1460-2075.1992.tb05481.x · DOI
  17. Finger, 1997, The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors, Gene, 197, 177, 10.1016/S0378-1119(97)00260-6 · DOI
  18. Zhang, 2004, Structural and functional analysis of the costimulatory receptor programmed death-1, Immunity, 20, 337, 10.1016/S1074-7613(04)00051-2 · DOI
  19. Terawaki, 2011, IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity, J. Immunol., 186, 2772, 10.4049/jimmunol.1003208 · DOI
  20. Tseng, 2001, B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells, J. Exp. Med., 193, 839, 10.1084/jem.193.7.839 · DOI
  21. Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 · DOI · Paper page
  22. Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364, 2517, 10.1056/NEJMoa1104621 · DOI · Paper page
  23. Schadendorf, 2015, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma, J. Clin. Oncol., 33, 1889, 10.1200/JCO.2014.56.2736 · DOI · Paper page
  24. Wolchok, 2010, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, Lancet Oncol., 11, 155, 10.1016/S1470-2045(09)70334-1 · DOI · Paper page
  25. Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med., 369, 134, 10.1056/NEJMoa1305133 · DOI
  26. Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol., 16, 908, 10.1016/S1470-2045(15)00083-2 · DOI
  27. Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  28. Chow, 2016, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase ib KEYNOTE-012 expansion cohort, J. Clin. Oncol.
  29. Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N. Engl. J. Med., 376, 1015, 10.1056/NEJMoa1613683 · DOI · Paper page
  30. Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
  31. Topalian, 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J. Clin. Oncol., 32, 1020, 10.1200/JCO.2013.53.0105 · DOI · Paper page
  32. Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 · DOI · Paper page
  33. Sweis, 2016, Emerging role of immunotherapy in urothelial carcinoma-immunobiology/biomarkers, Urol. Oncol., 34, 556, 10.1016/j.urolonc.2016.10.006 · DOI
  34. Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 · DOI · Paper page
  35. Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 · DOI · Paper page
  36. Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc. Natl. Acad. Sci. U. S. A., 107, 4275, 10.1073/pnas.0915174107 · DOI · Paper page
  37. Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N. Engl. J. Med., 372, 2006, 10.1056/NEJMoa1414428 · DOI · Paper page
  38. Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030 · DOI · Paper page
  39. Fecher, 2013, Ipilimumab and its toxicities: a multidisciplinary approach, Oncologist, 18, 733, 10.1634/theoncologist.2012-0483 · DOI · Paper page
  40. Luke, 2015, PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma, Oncotarget, 6, 3479, 10.18632/oncotarget.2980 · DOI
  41. De Velasco, 2017, Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients, Cancer Immunol. Res., 28
  42. Cappelli, 2016, Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities, RMD Open, 2, e000321, 10.1136/rmdopen-2016-000321 · DOI
  43. Hughes, 2015, Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy, Diabetes Care, 38, e55, 10.2337/dc14-2349 · DOI
  44. Okamoto, 2016, Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy, J. Diabetes Invest., 7, 915, 10.1111/jdi.12531 · DOI
  45. Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082 · DOI · Paper page
  46. Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 · DOI · Paper page
  47. Gajewski, 2010, Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy, Cancer J., 16, 399, 10.1097/PPO.0b013e3181eacbd8 · DOI · Paper page
  48. Spranger, 2016, Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma, Proc. Natl. Acad. Sci. U. S. A., 113, E7759, 10.1073/pnas.1609376113 · DOI
  49. Sweis, 2016, Analysis of impact of post-treatment biopsies in phase I clinical trials, J. Clin. Oncol., 34, 369, 10.1200/JCO.2015.63.6126 · DOI
  50. Sweis, 2015, Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer, ASCO Meet. Abstr., 33, 4511
  51. Peng, 2016, Loss of PTEN promotes resistance to t cell-mediated immunotherapy, Cancer Discov., 6, 202, 10.1158/2159-8290.CD-15-0283 · DOI · Paper page
  52. Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N. Engl. J. Med., 375, 819, 10.1056/NEJMoa1604958 · DOI · Paper page
  53. Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, 350, 1084, 10.1126/science.aac4255 · DOI · Paper page
  54. Vétizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126/science.aad1329 · DOI · Paper page
  55. Wang-Gillam, 2013, A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma, Invest. New Drugs, 31, 707, 10.1007/s10637-012-9866-y · DOI
  56. Brignone, 2010, First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity, J. Transl. Med., 8, 71, 10.1186/1479-5876-8-71 · DOI

Cited by

Sorted by citations

Metadata

Authors
Sweis, R. F., & Luke, J. J.
Affiliations
University of Chicago (US)
Corresponding author
Luke, Jason J.
ORCID
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2017-06
Volume
120
Pages
1-9
ISSN
1043-6618 (ISSN-L)
DOI
10.1016/j.phrs.2017.03.012
PMC
PMC5419683
OpenAlex
W2596337597
Cited by
37
References
8
Citations by year
2026: 1 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 11 · 2017: 7
FWCI
0.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacological Research (acceptedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH (T32 GM007019)
  • AACR (16-40-15-SWEI)
  • DOD (CA160315)
  • Arthur J. Schreiner Family Melanoma Research Fund
  • J. Edward Mahoney Foundation Research Fund
  • Brush Family Immunotherapy Fund
  • Diana and Andrew Da Miano Research Fund
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
immune checkpoint inhibitors, cancer immunotherapy, CTLA-4, PD-1, antitumor immunity, predictive biomarkers, immune-related adverse events, resistance mechanisms, antibody therapy
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Animals, Antibodies, Monoclonal, Humans, Immunity, Immunotherapy, Neoplasms, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review